The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, Robin L, Goodwin, Guy M·2017·Neuropsychopharmacology
DOI 10.1038/npp.2017.84

Cited by (702)

Items 501–600 of 702

  1. THE SEROTONIN 5-HT2ARECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET
    Andrew A. Bolinger, Noelle C. Anastasio, Kathryn A. Cunningham, Jia Zhou · 2023 · Medicinal chemistry reviews
  2. Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
    Payal Ghosh, Debjeet Sur · 2024 · Current Psychiatry Research and Reviews
  3. Resurrecting Ancestral Familial Health: A Role for Psilocybin?
    Ashley Glowiak · 2024 · The Family Journal
  4. Toxin Concerns and Safe Consumption of Edible Mushroom
    Odangowei Inetiminebi Ogidi, Patrick Chukwudi Adigwe · 2025 · Reference series in phytochemistry
  5. Evidence-Based Therapy Models in a New Age of Psychedelic-Assisted Psychotherapy
    Adith V. Ram, Katherine L. Abraham, Eric A. Storch · 2025 · Journal of Cognitive Psychotherapy
  6. Psychedelic Unselfing and Moral Perception : A Philosophical Account of the Change of Values Induced by Psychedelic Experiences
    Juuso Kähönen · 2020 · Työväentutkimus Vuosikirja
  7. Impact of People Access to Public Drugs on Substance Abuse and Delinquency Behavior in Thailand: Mediating Role of Life Satisfaction
    Kittisak Jermsittiparsert, Sakapas Saengchai, Jintana Pattanapongthorn · 2019 · Systematic Reviews in Pharmacy
  8. Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of MDMA
    Tudor M. Ionescu, Mario Amend, Tadashi Watabe, Jun Hatazawa, Andreas Maurer, Gerald Reischl, Bernd Jürgen Pichler, Hans F. Wehrl, Kristina Herfert · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  9. The Efficacy of PRISTINE: Revealing Concealed Opioid Crisis Trends via Reddit Examination
    Abdulaziz Alhamadani, Shailik Sarkar, Srishti Behal, Lulwah Alkulaib, Chang‐Tien Lu · 2023 · Research Square
  10. Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study
    Jacob S. Aday, Emily K. Bloesch, Alan K. Davis, Sarah E. Domoff, Kyle Christopher Scherr, Joshua D. Woolley, Christopher C. Davoli · 2023
  11. Ibogaine as a Treatment For Alcohol Use Disorder: a Preclinical Investigation
    Sarah Falkenhaug · 2023
  12. A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
    Stephanie L. Haft, Amanda E. Downey, Marissa Raymond‐Flesch, Gisele Fernandes‐Osterhold, Ellen Bradley, Aoife O’Donovan, Joshua D. Woolley · 2024
  13. Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin
    Ross J. Purple, Rahul Gupta, Christopher W. Thomas, Caroline T. Golden, Seán Froudist‐Walsh, Matthew W. Jones · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  14. Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging
    Hanna M. Tolle, Andrea I. Luppi, Timothy Lawn, Leor Roseman, David Nutt, Robin Lester Carhart-Harris, Pedro A. M. Mediano · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  15. When the therapist hallucinates: AI, psychedelics, and the risks of unsupervised digital mental health care
    Michael R. MacIntyre · 2026 · Digital Health
  16. Reviews of Note: A Future for Psychedelic Psychiatry?
    Peter Roy‐Byrne · 2017 · Journal watch
  17. Alteration of Monoaminergic Neuronal Firing by Acute Administration of Cariprazine: An In Vivo Electrophysiological Study
    Herman, Anna · 2017 · uO Research (University of Ottawa)
  18. Lucy in the sky with ketamine
    Katrin Weigmann · 2018 · EMBO Reports
  19. What Are the Appropriate Boundaries of Imagination?
    James M. Ellison, Helen H. Kyomen · 2019 · American Journal of Geriatric Psychiatry
  20. Bis(4-hydroxy-N,N-di-n-propyltryptammonium) fumarate tetrahydrate
    A.R. Chadeayne, Duyen N. K. Pham, James A. Golen, David R. Manke · 2019 · IUCrData
  21. P.324 Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state
    Natasha Leigh Mason, Kim P. C. Kuypers, Johannes T. Reckweg, Desmond H. Y. Tse, Felix Müller, Stefan W. Toennes, Amanda Feilding, Johannes Gerardus Ramaekers · 2020 · European Neuropsychopharmacology
  22. Club Drugs and Novel Psychoactive Substances
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  23. A Brief History of NPS Production and Distribution
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  24. Stimulant Drugs: Synthetic Cathinones
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  25. Stimulant Drugs: Methamphetamine
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  26. Classification Framework for Club Drugs and NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  27. Stimulant Drugs: Amphetamine-Type Stimulants
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  28. Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  29. The Clinical Challenge of Club Drugs and NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  30. Depressant Drugs: Benzodiazepine NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  31. Stimulant Drugs: Cocaine
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  32. Synthetic Cannabinoid Receptor Agonists (SCRAs)
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  33. Stimulant Drugs: MDMA and Drugs with Similar Effects
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  34. What Are Club Drugs and NPS and Why Are They Important?
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  35. Unmet need in depression: Psilocybin, a breakthrough treatment option
    Yogesh Kumar Chahar · 2021 · International Journal of Advanced Research in Medicine
  36. Vislumbrar de forma Mística
    Gilberto Palma Ramírez, Johali Priscila Flores Bustillos · 2021 · Educación y Salud Boletín Científico Instituto de Ciencias de la Salud Universidad Autónoma del Estado de Hidalgo
  37. Avaliação das possíveis interações entre o canabidiol e a ayahuasca em voluntários saudáveis: um estudo randomizado, duplo-cego e controlado com placebo
    Giordano Novak Rossi · 2020
  38. The Effect of Psilocybin on Personality
    Ravital LaBua · 2021 · CUNY Academic Works (City University of New York)
  39. 601 津八幡宮祭礼絵巻からみる近世初期津城下町と町屋 : ニューヨークパブリックライブラリー蔵 津八幡宮祭礼絵巻の建築史的研究(歴史・意匠)
    正睦 副島, 洋一 菅原 · 2005 · 東海支部研究報告集
  40. Analysis of the self-ignition of a turbulent gas jet in a stream of oxidizing agent
    V. N. Strokin · 1972 · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
  41. 青山デザイン会議(Vol.161)商品開発ストーリーに学ぶアイデア発想術
    英之 高橋, 淳 舛田, 由樹 山本 · 2013 · ブレーン
  42. P.0064 Rapid-acting antidepressants in motivation: the effects of low-dose ketamine and the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in the rat progressive ratio task
    Fionn Dunphy-Doherty, John Richard Kelly, Jack A. Prenderville · 2021 · European Neuropsychopharmacology
  43. Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  44. Concluding Remarks
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  45. Depressant Drugs: Introduction
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  46. Depressant Drugs: Ketamine and Its Analogues
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  47. Introduction
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  48. Hallucinogens
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  49. Psychedelics Road Ahead: Are We Ready?
    M R Nagendra Gowda · 2022 · Indian Journal of Private Psychiatry
  50. Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions
    Nestor Girala · 2022
  51. Psychedelic Drugs and Personality
    James W. B. Elsey, Linos Vossoughi · 2020 · Springer eBooks
  52. The good, the bad, and the intoxicated
    Natasha Leigh Mason · 2021
  53. Faculty Opinions recommendation of Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents.
    Eric Hollander, Genoveva Uzunova · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  54. Faculty Opinions recommendation of Psychedelics promote structural and functional neural plasticity.
    Edwin R. Chapman, Jason Vevea · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  55. Psychopharmacology
    Dan Joseph Stein · 2021 · Elsevier eBooks
  56. Index
    Owen Bowden‐Jones, Dima Abdulrahim · 2020 · Cambridge University Press eBooks
  57. Psychedelic Drugs and Personality
    James W. B. Elsey, Linos Vossoughi · 2018 · Springer eBooks
  58. Well-Being and the Outdoors: An Environmentalism Study Among a Religious Student Population
    Laura Pires-Gifford, Shaylee Hoffmann, Edmond Arroyo, Nathan Jones, Bethany Waite, Robert R. Wright · 2022 · Psi Chi Journal of Psychological Research
  59. INVITED EDITORIAL: Sharing Effective Models of Student Research Mentoring: Stories From Associate Editors
    Robert R. Wright, Kimberli R. H. Treadwell, Jennifer L. Hughes · 2022 · Psi Chi Journal of Psychological Research
  60. Psychopharmacology and social psychiatry
    Ursula Werneke · 2022 · Oxford University Press eBooks
  61. Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
    Jennings Hernandez · 2023 · Advances in Research
  62. Historical overview
    Chase W. Thompson, Muhammad Ishrat Husain · 2023
  63. Rychle působící antidepresiva -otázky a odpovědi
    Libor Ustohal, Eliška Bartečková · 2023 · Psychiatrie pro praxi
  64. Utilizing new technologies to measure therapy effectiveness for mental and physical health
    Jonathan E. Ossie · 2023
  65. Reply to: Marketing pitches of ‘magic mushrooms’ and ‘psychedelics’ mask that psychotomimetics use exposes those vulnerable to serious adverse effects
    Emma E. Morton, Kimberly Sakai, Amir Ashtari, Mollie M. Pleet, Erin E. Michalak, Josh D. Woolley · 2023 · Journal of Psychopharmacology
  66. Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain
    Nicholas Kolbman, Tiecheng Liu, Peter R. Guzzo, Jim Gilligan, George A. Mashour, Giancarlo Vanini, Dinesh Pal · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  67. Unlocking the potential of psychedelics as medicine: Past obstacles and future outlooks
    Sharon Y. Kim, Rayven-Nikkita Collins, Jimmy Teng, Leanna Kalinowski · 2023 · MIT Science Policy Review
  68. Cultural Biases and Psychedelic Experiences: Western Scientific Perspectives about Amazonian Mestizo Therapeutic Traditions
    Alberto Dubbini · 2023 · OBM Integrative and Complementary Medicine
  69. Psychonautical engineering: Synergizing the magic of mindfulness, mushrooms, and mindsets for police officer well-being
    Renae M. Stevenson · 2023 · Journal of Community Safety and Well-Being
  70. Experiencias y enfoques de trabajo de los facilitadores de estados expandidos de consciencia, alcanzados mediante la LSD
    Verónica María Peña Garcia · 2023 · Cultura y Droga
  71. Profit and Prudence: Navigating Psychedelic Commercialization Through Lessons from the Prescription Opioid Crisis
    Daniel Eisenkraft Klein · 2023 · Health Policy
  72. O Uso da ibogaína no manejo da dependência de drogas no Brasil
    Bruno Ramos Gomes · 2021
  73. Farmakológiai biopolitikák (1. rész) : A lélek vegyészete
    Ágnes Básthy, Zoltán Lengyel · 2023 · Replika
  74. Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
    Laetitia Vanderijst, Felix Hever, Anne Buot, Charles Dauré, Janaïna Benoit, Catherine Hanak, Johannes Veeser, Margot Morgiève, Salvatore Campanella, Charles Kornreich et al. · 2024 · Research Square
  75. Absurdity and Serendipity: Reclined domain for Innovations and Researchers/Discoveries
    Tahir Nasir · 2024 · European journal of applied sciences
  76. Serine 3.39 and isoleucine 4.60 are key sites for 5‐HT 2A R‐mediated G s signaling
    Lingmeng Xie, Xiaoqian Liu, Yishan Yao, Bo Tan, Ruibin Su · 2024 · FEBS Letters
  77. "Vine of the Soul": The Potential of Ayahuasca for Reducing Depression, Anxiety, and Stress among Ceremony Participants and the Role of Rumination
    Banan Ramarushton · 2024
  78. LEADERSHIP IN THE DIGITAL AGE: NAVIGATING COMPLEXITY THROUGH CRITICAL THINKING, CREATIVITY, AND UNCONVENTIONAL APPROACHES
    LENKA ČADOVÁ, Jakub Stříbrný, PAVEL SLÁDEK · 2024 · AD ALTA Journal of Interdisciplinary Research
  79. Farmakodinamika psihoaktivnih učinkovin in mehanizmi odvisnosti
    Marko Milojević, Tina Maver, Uroš Maver · 2024
  80. An exploration of psychotherapists' readiness to join the psychedelic renaissance
    Siobhan Scanlon, Gráinne Donohue · 2024 · Counselling and Psychotherapy Research
  81. The Use of Psychedelics as an Adjunct to Psychotherapy
    Jean Schulthess Watt · 2024 · Psychotherapie-Wissenschaft
  82. Microdosing Psychedelics as a Promising New Pharmacotherapeutic
    Kim P. C. Kuypers · 2024 · Springer eBooks
  83. Phase 1 clinical trial on Orgasmic Meditation (OM): Assessing safety and feasibility as a meditation practice for individuals with PTSD
    Daniel Kriegman, Rachel Pelletier, Caroline Griggs, Caryn Roth · 2025 · Contemporary Clinical Trials Communications
  84. A Historical and Global Overview of Neuropsychology
    Caetano Schmidt Gundlach Knop-Máximo, Vanessa de Almeida Signori, Luís Felipe da Silva Rodrigues, Mariana Esteves Felix Penha, Déborah Amaral de Azambuja, Cláudia Berlim de Mello · 2025 · Springer eBooks
  85. Speech markers of psychedelic-induced psychological change
    Joanna Kuc, Rosalind G. McAlpine, Amelia Sellers, George Blackburne, Daniel Robert Lametti, Jeremy I Skipper · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  86. ANALYSIS OF THE PROBLEM OF CONSCIOUSNESS USING THE LAW OF THE ABSENCE OF ABSOLUTE NOTHINGNESS
    Varol Koç · 2025 · Akademik Hassasiyetler
  87. Cornutopia: A short story and what it can tell us about ethnic minority views on psychedelic research, and the potential impact on clinical outcomes
    Caroline Hayes · 2025 · Journal of Psychedelic Studies
  88. Toxin Concerns and Safe Consumption of Edible Mushroom
    Odangowei Inetiminebi Ogidi, Patrick Chukwudi Adigwe · 2025 · Reference series in phytochemistry
  89. Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany
    Sebastian Sattler, Suzanne C. Wood, Margit Anne Petersen, Fiona Seiffert, Guido Mehlkop · 2025 · Scientific Reports
  90. Natural Guardians of the Balkans: Entheogens in Indigenous Practices and Their Implications for Well-Being and Therapy
    Lucija Vejmelka, Damir Gašpar · 2025 · Psychoactives
  91. Is there mush-room to improve the environmental sustainability of psilocybin production?
    Luke Lanham, Alistair R. McTaggart, James Robert Falconer · 2025 · Journal of CO2 Utilization
  92. Fear as medicine: A mixed-methods analysis of 5-MeO-DMT, mental health, and intergenerational healing
    Jeffrey S. Overall · 2025 · Applied Psychology Research
  93. Factors associated with psychedelic attitudes and usage among college students
    Wei‐Chin Hwang, Yuhan Kong, Ken Fujimoto, Janet Cen, Alvin Villarosa · 2025 · Journal of Psychedelic Studies
  94. Mécanismes d’action et perspectives thérapeutiques du LSD : état des lieux actuel
    Amel Bouloufa, Sarah Delcourte, Nasser Haddjeri · 2025 · Biologie Aujourd hui
  95. A reciprocal interplay between 5-HT 2A and mGlu 5 receptors underlies neuroplasticity
    Tomas del Olmo, Mathilde Decourcelle, Martial Sevéno, Joël Bockaert, Philippe Marin, Carine Bécamel · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  96. Neurocognitive Factors in Spiritual Experiences and Practices
    Nikola Boris Kohls, James Giordano · 2025 · Springer eBooks
  97. Exploring the Influence of Genetic Variation in the HTR2A Gene on the Pharmacodynamic Response to Antipsychotic Medications
    Saanvi Kondapelli · 2025 · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT
  98. Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review
    Brett Hughes, Soz Mirza, Manasi Ponamala, James Sagaser, Riley Paredes, Naomi Hematillake, Chandni Tailor, Rahim Khan, Sudhakar Pemminati · 2025 · Cureus
  99. Behavioral and genetic analysis of the effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in C. elegans
    Amanda M. White, Adele D. Bauer, Serge Faumont, Shawn R. Lockery · 2025 · PLoS ONE
  100. Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
    Guilllermo Castaño-Perez, Sara Isabel Castaño-Ocampo · 2025 · Pharmaceutical science.